Magnus Medical Inc. has taken formal steps to protect the intellectual property behind SAINT accelerated depression therapy, reinforcing its commitment to innovation and patient safety. The company recently issued cease-and-desist letters to organizations it believes infringe on patents covering its accelerated neuromodulation protocols.
Protecting the Innovation Behind SAINT Accelerated Depression Therapy
As the exclusive licensee of patents assigned by Stanford University, Magnus Medical holds U.S. Patent Nos. 10,595,735 and 11,839,455. These patents protect systems and methods that enable accelerated theta-burst stimulation (aTBS) for neurological conditions such as major depressive disorder (MDD) and treatment-resistant depression (TRD).
Importantly, these patents reflect years of peer-reviewed research conducted within the Stanford academic system. Therefore, safeguarding SAINT accelerated depression therapy ensures that patients receive rigorously validated treatment grounded in scientific evidence.
Brandon Bentzley, M.D., Ph.D., co-founder and chief science officer of Magnus Medical, emphasized that protecting intellectual property preserves treatment integrity. He co-developed SAINT alongside the late Nolan Williams, M.D., at Stanford. According to Bentzley, maintaining strict IP standards supports high-quality outcomes and protects patients from unvalidated protocols.
Cease-and-Desist Letters Reinforce IP Enforcement
Magnus Medical actively monitors the neuromodulation market to ensure alignment with its patent rights. As a result, the company sent cease-and-desist notices to entities it believes are commercializing accelerated protocols that may infringe its patents.
Christian Gormsen, CEO of Magnus Medical, stated that failure to respect intellectual property frameworks can undermine academic innovation and mislead providers and patients. While the company welcomes properly licensed innovation, it will continue to defend the IP behind SAINT accelerated depression therapy.
Clinical Validation and Growing Adoption
To date, more than 700 patients have received SAINT accelerated depression therapy across research and commercial settings. Verified providers include leading institutions such as Stanford Health, Sutter Health, Medical University of South Carolina, University of Arkansas for Medical Sciences, and LSU Health.
Notably, SAINT is the first FDA-cleared accelerated neuromodulation protocol of its kind. Published clinical studies report a 79% remission rate, with patients reaching remission in an average of 2.6 days during a five-day treatment course. The protocol integrates functional MRI brain mapping, intelligent aTBS delivery, and proprietary targeting algorithms to personalize treatment at the neural circuit level.
Overall, Magnus Medical’s actions aim to protect both its patented technology and the broader integrity of accelerated neuromodulation therapies in the evolving mental health landscape.
Read Also: Best Travel Insurance for Pre-Existing Conditions 2026: Generali Global Assistance Recognized
